Analysis of baseline characteristics, disease burden and long-term follow-up of 167 patients with Paroxysmal Nocturnal Hemoglobinuria at a single center in Brazil-Reference-Cited by-同舟云学术

Analysis of baseline characteristics, disease burden and long-term follow-up of 167 patients with Paroxysmal Nocturnal Hemoglobinuria at a single center in Brazil

Published:2021-12 Issue: Volume:92 Page:102605
ISSN:1079-9796
Container-title:Blood Cells, Molecules, and Diseases
language:en
Short-container-title:Blood Cells, Molecules, and Diseases

Author:

de Azambuja Ana Paula,Oliveira Michel Michels,Bitencourt Marco Antonio,Bonfim Carmem,Malvezzi Mariester,Pasquini Ricardo

Publisher

Elsevier BV

Subject

Cell Biology,Hematology,Molecular Biology,Molecular Medicine

Reference26 articles.

1. Natural history of paroxysmal nocturnal;Hillmen;N. Engl. J. Med.,1995

2. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry;Borowitz;Cytometry B Clin. Cytom.,2010

3. Use of a FLAER-based WBC assay in the primary screening of PNH clones;Sutherland;Am. J. Clin. Pathol.,2009

4. Paroxysmal nocturnal hemoglobinuria;Parker;Curr. Opin. Hematol.,2012

5. 1972-Dacie_Lewis_Ser_Haematol__1972_5_3-23.pdf 1972.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical characteristics and management of paroxysmal nocturnal haemoglobinuria in Latin America: a narrative review;Annals of Hematology;2024-09-05

2. Efficacy and safety of current treatments for paroxysmal nocturnal hemoglobinuria: A systematic review;Clinical Immunology Communications;2023-12

3. Characteristics of paroxysmal nocturnal hemoglobinuria patients in Brazil: A retrospective administrative claims database analysis of PNH patients in Brazilian public healthcare system;PLOS ONE;2023-07-26

4. Paroxysmal nocturnal hemoglobinuria: Where we stand;American Journal of Hematology;2023-01-16

5. Using 5 consecutive years of NICE guidance to describe the characteristics and influencing factors on the economic evaluation of orphan oncology drugs;Frontiers in Public Health;2022-09-14